Image

IVUS-guided DK Crush Stenting Technique for Patients With Complex Bifurcation Lesions

IVUS-guided DK Crush Stenting Technique for Patients With Complex Bifurcation Lesions

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study is designed to investigate whether IVUS-guided DK crush stenting technique compared to angiography-guided DK crush after the indexed procedure will lead to lower rates of the composite endpoint of target vessel failure (TVF) at 12 months. The individual components of TVF include cardiac death, target-vessel myocardial infarction (MI), or target vessel revascularization (TVR). Complex bifurcation lesions were defined according to DEFINITION study.

Description

This is a prospective, multi-center, randomized-controlled, single blind, superiority trial that will include 35 international sites. The investigators aim to enroll 556 subjects with complex coronary bifurcation lesions in native coronary arterial segments.

All patients with complex coronary bifurcation lesions suitable for DES implantation will undergo 1:1 randomization either to IVUS-guided or angiography-guided DK crush stenting using a randomization schedule blocked by site.

All subjects will be screened according to the predefined inclusion and exclusion criteria per protocol and will further undergo angiography before DES implantation. Data and images will be collected during the index procedure, during re-intervention in the case of clinically driven TVF, and at the predefined 12-month clinical follow-up visit. All subjects will also undergo angiographic follow-up at 13 months.

Eligibility

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures;
  2. Men and women 18 years and older;
  3. Established indication for PCI according to the guidelines of ACC/AHA;
  4. Native coronary lesion suitable for drug-eluting stent placement;
  5. True bifurcation lesions (Medina 0,1,1/1,1,1), lesions length≤ 68 mm
  6. Reference vessel diameter in side branch > 2.5mm by visual estimation;
  7. Complex bifurcation lesions based on the DEFINITION study.

Exclusion Criteria:

  1. Pregnancy and breast feeding mother;
  2. Co-morbidity with an estimated life expectancy of < 50 % at 12 months;
  3. Scheduled surgery interrupting antiplatelet medications in the next 6 months;
  4. Intolerable to DAPT;
  5. Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk;
  6. Unable to provide written informed consent, or fail to follow the protocol;
  7. Previous enrolment in coronary intervention device investigation during the study period;
  8. Lesion cannot be covered by 2 longest stents;
  9. Restenotic bifurcation lesions;
  10. Severe calcification requiring rotational atherectomy;
  11. Acute myocardial infarction less than 24 hours;
  12. Chronic total occlusion which is not recanalized;
  13. Simple bifurcation lesions;
  14. Renal failure requiring or during dialysis;
  15. Hemoglobin <9g/L
  16. Uncontrolled hypertension (systolic blood pressure≥180 mmHg or diastolic blood pressure≥110 mmHg)
  17. Severe heart failure (LVEF<30%)
  18. Combined pre- and post-capillary hypertension (mPAP≥25 mmHg, PCWP>15 mmHg, and PVR>3.0 WU)
  19. Patients with hypertrophic obstructive cardiomyopathy.

Study details
    Coronary Artery Disease

NCT03770650

Nanjing First Hospital, Nanjing Medical University

26 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.